Importantly,the objective of these studies was only to validate the invivo activity of stable macromolecular diABZI agonists ratherthan to engineer constructs for maximal antitumor efficacy or to investigatethe impact of STING activation on antitumor immunity or the tumormicroenvironment, which we and others have described previously acrossa range of tumor types.,−,  However, these findings motivate future work focused on leveragingboth stable and cleavable conjugates to optimally balance diABZI potencyand pharmacological properties for disease-specific applications. This evidence concerns the gene STING1 and neoplasm.